| Triazole–dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration YC Zheng, YC Duan, JL Ma, RM Xu, X Zi, WL Lv, MM Wang, XW Ye, ... Journal of medicinal chemistry 56 (21), 8543-8560, 2013 | 239 | 2013 |
| A systematic review of histone lysine‐specific demethylase 1 and its inhibitors YC Zheng, J Ma, Z Wang, J Li, B Jiang, W Zhou, X Shi, X Wang, W Zhao, ... Medicinal research reviews 35 (5), 1032-1071, 2015 | 210 | 2015 |
| Design, synthesis, and structure–activity relationship of novel LSD1 inhibitors based on pyrimidine–thiourea hybrids as potent, orally active antitumor agents LY Ma, YC Zheng, SQ Wang, B Wang, ZR Wang, LP Pang, M Zhang, ... Journal of medicinal chemistry 58 (4), 1705-1716, 2015 | 173 | 2015 |
| Design, synthesis and antiproliferative activity studies of novel 1, 2, 3-triazole–dithiocarbamate–urea hybrids YC Duan, YC Zheng, XC Li, MM Wang, XW Ye, YY Guan, GZ Liu, ... European journal of medicinal chemistry 64, 99-110, 2013 | 128 | 2013 |
| Natural product-derived spirooxindole fragments serve as privileged substructures for discovery of new anticancer agents B Yu, YC Zheng, XJ Shi, PP Qi, HM Liu Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2016 | 120 | 2016 |
| USP7: Novel Drug Target in Cancer Therapy ZWWKYYJPHRZHSHMLYC Zheng* Frontiers in Pharmacology, 2019 | 108 | 2019 |
| Design and synthesis of novel 1, 2, 3-triazole–pyrimidine–urea hybrids as potential anticancer agents LY Ma, B Wang, LP Pang, M Zhang, SQ Wang, YC Zheng, KP Shao, ... Bioorganic & Medicinal Chemistry Letters 25 (5), 1124-1128, 2015 | 106 | 2015 |
| Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma Y Lu, YT Chan, HY Tan, C Zhang, W Guo, Y Xu, R Sharma, ZS Chen, ... Journal of Experimental & Clinical Cancer Research 41, 1-17, 2022 | 99 | 2022 |
| Irreversible LSD1 inhibitors: application of tranylcypromine and its derivatives in cancer treatment Y C Zheng, B Yu, G Z Jiang, X J Feng, P X He, X Y Chu, W Zhao, H M Liu Current topics in medicinal chemistry 16 (19), 2179-2188, 2016 | 99 | 2016 |
| Synthesis and biological evaluation of coumarin–1, 2, 3-triazole–dithiocarbamate hybrids as potent LSD1 inhibitors XW Ye, YC Zheng, YC Duan, MM Wang, B Yu, JL Ren, JL Ma, E Zhang, ... MedChemComm 5 (5), 650-654, 2014 | 94 | 2014 |
| Skp2 in the ubiquitin‐proteasome system: a comprehensive review MD Asmamaw, Y Liu, YC Zheng, XJ Shi, HM Liu Medicinal Research Reviews 40 (5), 1920-1949, 2020 | 87 | 2020 |
| Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment YC Duan, YC Ma, WP Qin, LN Ding, YC Zheng, YL Zhu, XY Zhai, J Yang, ... European journal of medicinal chemistry 140, 392-402, 2017 | 82 | 2017 |
| Efficient synthesis of new antiproliferative steroidal hybrids using the molecular hybridization approach B Yu, PP Qi, XJ Shi, R Huang, H Guo, YC Zheng, DQ Yu, HM Liu European Journal of Medicinal Chemistry 117, 241-255, 2016 | 79 | 2016 |
| TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy YC Zheng, B Yu, ZS Chen, Y Liu, HM Liu Epigenomics 8 (5), 651-666, 2016 | 79 | 2016 |
| Discovery of [1,2,3]Triazolo[4,5-d]pyrimidine Derivatives as Novel LSD1 Inhibitors ZH Li, XQ Liu, PF Geng, FZ Suo, JL Ma, B Yu, TQ Zhao, ZQ Zhou, ... ACS Medicinal Chemistry Letters 8 (4), 384-389, 2017 | 73 | 2017 |
| Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A) Z Li, L Ding, Z Li, Z Wang, F Suo, D Shen, T Zhao, X Sun, J Wang, Y Liu, ... Acta Pharmaceutica Sinica B 9 (4), 794-808, 2019 | 72 | 2019 |
| LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer DD Shen, JR Pang, YP Bi, LF Zhao, YR Li, LJ Zhao, Y Gao, B Wang, ... Molecular cancer 21 (1), 75, 2022 | 71 | 2022 |
| Design, synthesis and biological evaluation of [1, 2, 4] triazolo [1, 5-a] pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors S Wang, LJ Zhao, YC Zheng, DD Shen, EF Miao, XP Qiao, LJ Zhao, Y Liu, ... European journal of medicinal chemistry 125, 940-951, 2017 | 70 | 2017 |
| Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing Z Wang, W Kang, O Li, F Qi, J Wang, Y You, P He, Z Suo, Y Zheng, ... Acta pharmaceutica sinica B 11 (3), 694-707, 2021 | 65 | 2021 |
| Tranylcypromine based lysine-specific demethylase 1 inhibitor: summary and perspective XJ Dai, Y Liu, XP Xiong, LP Xue, YC Zheng, HM Liu Journal of Medicinal Chemistry 63 (23), 14197-14215, 2020 | 65 | 2020 |
Hong-Min LiuZhengzhou University在 zzu.edu.cn 的电子邮件经过验证
